Revenue (Tables)

9 Months Ended

Sep. 30, 2019

Revenue

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2019		2018		2019		2018
Janssen	$	8,807	$	8,866	$	21,522	$	21,044
Alfasigma		23		117		121		10,650
Other		6		6		23		50
Total collaboration revenue	$	8,836	$	8,989	$	21,666	$	31,744

Summary of changes in deferred revenue

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2019		2018		2019		2018
Collaboration revenue recognized in the period from:
Amounts included in deferred revenue at the beginning of the period	$	8,836	$	7	$	21,661	$	39
Performance obligations satisfied in previous period		—		—		—		—

Summary of profit sharing revenue and collaboration loss

	Three Months Ended		Nine Months Ended
	September 30,		September 30,
(In thousands)	2019		2019
Mylan collaboration agreement - Amounts receivable from Mylan	$	3,591	$	3,749
Collaboration loss - Amounts payable to Mylan	$	—	$	1,582

Summary of reductions to R and D costs related to the reimbursement payments

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2019		2018		2019		2018
Janssen	$	930	$	610	$	3,125	$	610
Mylan		53		2,598		287		5,843
Total reduction to R&D expense	$	983	$	3,208	$	3,412	$	6,453